EP1339429A4 - Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire - Google Patents

Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire

Info

Publication number
EP1339429A4
EP1339429A4 EP01986043A EP01986043A EP1339429A4 EP 1339429 A4 EP1339429 A4 EP 1339429A4 EP 01986043 A EP01986043 A EP 01986043A EP 01986043 A EP01986043 A EP 01986043A EP 1339429 A4 EP1339429 A4 EP 1339429A4
Authority
EP
European Patent Office
Prior art keywords
vitamin
calcium
composition containing
cardiovascular health
improved cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01986043A
Other languages
German (de)
English (en)
Other versions
EP1339429A2 (fr
Inventor
Adrianne Bendich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1339429A2 publication Critical patent/EP1339429A2/fr
Publication of EP1339429A4 publication Critical patent/EP1339429A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une composition destinée à être administrée par voie orale, contenant un mélange d'une statine, d'acide docosahexaenoïque (DHA), de vitamine E, de vitamine C, de vitamine B6, de vitamine B12, d'acide folique, et de calcium avec un porteur adapté. Ces compositions sont particulièrement adaptées en tant qu'additifs alimentaires administrés pour réduire les facteurs de risque de maladies cardiovasculaires, tels que des taux de cholestérol sérique et une pression artérielle élevés.
EP01986043A 2000-11-29 2001-11-29 Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire Withdrawn EP1339429A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25389900P 2000-11-29 2000-11-29
US253899P 2000-11-29
PCT/US2001/044734 WO2002043659A2 (fr) 2000-11-29 2001-11-29 Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire

Publications (2)

Publication Number Publication Date
EP1339429A2 EP1339429A2 (fr) 2003-09-03
EP1339429A4 true EP1339429A4 (fr) 2007-03-14

Family

ID=22962156

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01986043A Withdrawn EP1339429A4 (fr) 2000-11-29 2001-11-29 Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire

Country Status (6)

Country Link
EP (1) EP1339429A4 (fr)
JP (1) JP2004514684A (fr)
AU (1) AU3651102A (fr)
CA (1) CA2427618A1 (fr)
MX (1) MXPA03004818A (fr)
WO (1) WO2002043659A2 (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4611622B2 (ja) * 2002-07-11 2011-01-12 第一三共株式会社 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
WO2004006919A1 (fr) * 2002-07-11 2004-01-22 Sankyo Company, Limited Composition medicale pour reduire le taux de lipides sanguins ou le taux d'homocysteine sanguine
NZ539625A (en) * 2002-09-27 2007-11-30 Martek Biosciences Corp Improved glycemic control for Prediabetes and/or Diabetes Type II Using Docosahexaenoic Acid
MXPA05003347A (es) * 2002-09-27 2005-11-23 Martek Biosciences Corp Terapia profilactica con acido docosahexaenoico para pacientes con inflamacion subclinica.
FR2847472B1 (fr) * 2002-11-22 2006-08-11 Synergia Nouvelles compositions pharmaceutiques notamment pour la prevention des pathologies cardio-vasculaires
DE10261067A1 (de) * 2002-12-24 2004-08-05 Nutrinova Nutrition Specialties & Food Ingredients Gmbh Cholesterinsenkendes Mittel, enthaltend eine n-3-Fettsäure
AU2004305154A1 (en) * 2003-12-23 2005-07-07 Medicure International Inc. Combination therapies employing a composition comprising a HMG CoA reductase inhibitor and a vitamin B6 related compound
ITRM20040395A1 (it) * 2004-08-03 2004-11-03 Sigma Tau Ind Farmaceuti Composizione comprendente statine e acidi grassi omega 3.
NZ552389A (en) * 2004-08-06 2009-05-31 Transform Pharmaceuticals Inc Statin pharmaceutical compositions and related methods of treatment
AU2005276686B2 (en) * 2004-08-23 2008-11-20 Unilever Plc Composition comprising statin
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
BRPI0518398A2 (pt) * 2004-12-06 2008-11-18 Reliant Pharmaceuticals Inc Ácidos graxos âmega-3 e agente deslipidÊmico para terapia de lipÍdeos
US20060135610A1 (en) * 2004-12-22 2006-06-22 Bortz Jonathan D Cardiovascular compositions
JP2009515816A (ja) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
US8962682B2 (en) 2005-11-11 2015-02-24 Mochida Pharmaceutical Co., Ltd. Jelly composition
EP2081550B2 (fr) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Revêtement de capsules avec des ingrédients pharmaceutiques actifs
US8784886B2 (en) * 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
ITMI20072142A1 (it) * 2007-11-08 2009-05-09 Yervant Zarmanian Composizioni farmaceutiche contenenti statine e derivati di acidi grassi omega-3
EP2308493A4 (fr) * 2008-07-07 2013-05-01 Mochida Pharm Co Ltd Agent améliorant ou thérapeutique pour une dyslipidémie
GB0818472D0 (en) * 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
ITFI20080243A1 (it) * 2008-12-15 2010-06-16 Valpharma Sa Formulazioni per la somministrazione orale di acidi grassi omega polienoici in combinazione con statine di origine naturale o semi-sintetica.
ES2661812T3 (es) * 2009-10-16 2018-04-04 Mochida Pharmaceutical Co., Ltd. Composiciones
CA2785296A1 (fr) 2009-12-23 2011-06-30 Claudio Cavazza Composition de combinaison utile pour le traitement de maladies cardiovasculaires
EP2654463B1 (fr) * 2010-12-21 2018-05-30 Omegatri AS Antioxydants dans la poudre et les comprimés à base d'huiles de poissons
KR101310710B1 (ko) * 2011-03-23 2013-09-27 한미약품 주식회사 오메가-3 지방산 에스테르 및 ＨＭＧ-ＣｏＡ 환원효소 억제제를 포함하는 경구용 복합 조성물
FR3007985A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament pour la prevention et le traitement des facteurs de risques cardiometaboliques, en particulier maladies cardiovasculaires, pre-diabete, diabete de type ii et steatose hepatique
FR3007986A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament destine a lutter contre l'infertilite et la sous-fertilite en particulier dans le cadre d'une sous fertilite ou infertilite metabolique
FR3007987A1 (fr) * 2013-07-02 2015-01-09 Internat Nutrition Res Company Medicament pour la prevention et le traitement de l'atherosclerose et du survieillissement metabolique
EP3046552A1 (fr) * 2013-07-02 2016-07-27 International Nutrition Research Company Composition intervenant dans la regulation du dysfonctionnement des cycles de l'energie, de l'inflammation et de l'insulinoresistance et son utilisation notamment dans les maladies cardiometaboliques
CA3020087A1 (fr) * 2016-04-14 2017-10-19 Michael LUCEY Compositions combinatoires et leurs methodes d'utilisation

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039053A2 (fr) * 1995-06-06 1996-12-12 Campbell Soup Company Complements alimentaires a base de mineraux pour repas dietetique
WO1997038694A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
DK0843972T3 (da) * 1996-11-20 2002-12-02 Nutricia Nv Næringsmiddelsammensætning, der indeholder fedtstoffer til behandling af stofskiftesygdomme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039053A2 (fr) * 1995-06-06 1996-12-12 Campbell Soup Company Complements alimentaires a base de mineraux pour repas dietetique
WO1997038694A1 (fr) * 1996-04-17 1997-10-23 Merck & Co., Inc. Therapie d'association destinee a reduire les risques lies a une maladie cardio-vasculaire

Also Published As

Publication number Publication date
JP2004514684A (ja) 2004-05-20
AU3651102A (en) 2002-06-11
WO2002043659A3 (fr) 2002-09-06
WO2002043659A2 (fr) 2002-06-06
MXPA03004818A (es) 2003-09-10
CA2427618A1 (fr) 2002-06-06
EP1339429A2 (fr) 2003-09-03

Similar Documents

Publication Publication Date Title
WO2002043659A3 (fr) Composition contenant des statines et du calcium destinee a ameliorer la sante cardiovasculaire
CN1117571C (zh) 改良的钙的饮食增补剂
MY162133A (en) Nutritional supplement containing long-chain polyunsaturated fatty acids
US20080114074A1 (en) Anti-atherosclerosis composition containing carotenoids and method for inhibiting ldl oxidation
RU2008116611A (ru) Способ снижения артериального давления у индивидов с состоянием, предшествующим гипертензии, и/или у индивидов с метаболическим синдромом
HK1052439A1 (en) Preparation for the prevention and/or treatment ofvascular disorders
NZ516101A (en) Pharmaceutical and nutritional compositions containing essential fatty acids and homocysteine-lowering agents
MXPA05009933A (es) Composiciones que comprenden acidos grasos y aminoacidos.
DE60005152D1 (de) Arzneimittel, nahrungszusätze und kosmetische zubereitung enthaltend eine fettsäure und ingwer
JP2002514574A (ja) 圧迫性潰瘍の治療のための栄養組成物
MXPA04000834A (es) Suplementos dieteticos de vinasa de vino y un proceso importante de produccion.
ATE538666T1 (de) Nahrungsergänzung zur verhinderung von abmagerungen
WO2002056708A3 (fr) Preparation destinee a ameliorer l'assimilation des aliments
CY1105732T1 (el) Μυρμηκικο ασβεστιο ως διαιτητικο συμπληρωμα
WO2006109194A3 (fr) Composes de chrome et d'acides gras et leurs procedes de fabrication et d'utilisation
WO2002043662A3 (fr) Composition dietetique contenant de l'acide linoleique conjugue et du calcium pour une meilleure sante
WO2003049687A3 (fr) Compositions medicinales et methodes therapeutiques
AU5634500A (en) Dietary calcium as a supplement to vitamin d compound treatment of multiple sclerosis
CA2408528A1 (fr) Sel de creatine presentant une efficacite nutritionnelle et therapeutique accrue et compositions contenant ce sel
WO2003002125A3 (fr) Combinaison de sucres amines et cysteine ou de derives de cysteine
PL367812A1 (en) Alpha-ketoglutarates of active ingredients and compositions containing same
WO2001024803A3 (fr) Compositions pharmaceutiques et leur utilisation
RU2003105695A (ru) Препарат с сосудозащищающим и антиокислительным действием и его применение
AU2003224107A1 (en) Soluble composition containing sporopollenin and the use thereof
EP1325747A3 (fr) Supplement diététique pour patients neuropathiques

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030624

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

R17D Deferred search report published (corrected)

Effective date: 20020906

A4 Supplementary search report drawn up and despatched

Effective date: 20070208

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/20 20060101ALI20070202BHEP

Ipc: A61K 31/525 20060101ALI20070202BHEP

Ipc: A61K 31/366 20060101ALI20070202BHEP

Ipc: A61K 31/714 20060101ALI20070202BHEP

Ipc: A61K 31/4415 20060101ALI20070202BHEP

Ipc: A61K 31/375 20060101ALI20070202BHEP

Ipc: A61K 31/355 20060101ALI20070202BHEP

Ipc: A61K 47/00 20060101AFI20020919BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070510